AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

DELTEX MEDICAL GROUP PLC

Share Issue/Capital Change Jul 1, 2014

7593_dirs_2014-07-01_46e49f0e-066e-405a-a7a0-0ab0af27d6b1.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1414L

Deltex Medical Group PLC

01 July 2014

Deltex Medical Group plc

("Deltex Medical" or the "Company")

Directors' Shareholdings/Issue of equity

1 July 2014 - Deltex Medical Group plc, the global leader in oesophageal Doppler monitoring ("ODM"), announces that it has issued a total of 438,193 new ordinary shares of 1p each in the Company ("New Ordinary Shares") at a price of 11.38 pence per share.

The three non-executive directors named below have elected to take 262,446 New Ordinary Shares in lieu of a cash payment as remuneration for their services to the Company for the period 1 January 2014 to 30 June 2014.

A former non-executive director has elected to take 70,299 New Ordinary Shares in lieu of a cash payment as remuneration for his service to the Company for the period 1 January 2014 to 7 May 2014.

In addition to the above, the Company also announces that it has today issued a total of 105,448 New Ordinary Shares to an advisor to the Company at a price of 11.38 pence per share.

Accordingly, application has been made for these New Ordinary Shares to be admitted to trading on AIM. The shares rank pari passu with the existing issued shares of the Company. Admission to trading on AIM and dealings in the New Ordinary Shares are expected to commence on 7 July 2014.  Following the issue of these new shares the Company will have a total of 213,017,689 ordinary shares of 1p each in issue.

Following this issue, the relevant directors' beneficial interests are as follows:

Name of Director Number of New Ordinary Shares issued in lieu of fees/salary Holding of shares following issue of New Ordinary Shares % of enlarged issued share capital
Nigel Keen 146,454 8,495,254 3.99
Sir Duncan Nichol 57,996 986,912 0.46
Julian Cazalet 57,996 4,592,809 2.16

For further information:

Deltex Medical Group plc 01243 774 837

[email protected]
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Paul Mitchell, Finance Director
Nominated Adviser & Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Joint Broker

Zeus Capital Limited

Dominic Wilson

John Goold
020 7533 7727
Financial Public Relations
Newgate Threadneedle 020 7653 9850
Caroline Forde
Heather Armstrong

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSLLFFEDSILIIS

Talk to a Data Expert

Have a question? We'll get back to you promptly.